Recruiting

Nusinersen

Sponsor:

Biogen

Code:

NCT05789758

Conditions

Muscular Atrophy, Spinal

Eligibility Criteria

Sex: Female

Age: 18 - 54

Healthy Volunteers: Not accepted

Interventions

No Intervention

Study Details

Brief summary:

In this study, researchers will know more about the effects of nusinersen, also known as Spinraza®, in pregnant participants with spinal muscular atrophy, also known as SMA. This is a drug available for doctors to prescribe for people with SMA. Due to the current treatment options that exist, people with SMA may now reach the age where they can become pregnant. But, there is not enough information known yet about what the effects of nusinersen may be on pregnant people with SMA or on their babies.

This is known as an "observational" study, which collects health information about study participants without changing their medical care. The pregnant participants for this study will be found using 3 different groups of SMA study research centers:

  • ISMAR-US (International SMA Registry in the United States)
  • UK Adult SMA-REACH (Adult SMA Research and Clinical Hub in the United Kingdom)
  • SMArtCARE (Austria, Germany, and Switzerland)

The main goal of this study is to collect birth and health information from 3 groups of participants and their babies. These groups are:

  • Those who received nusinersen 14 months before the first day of their last period before getting pregnant
  • Those who received nusinersen 14.5 months before the day they got pregnant
  • Those who received nusinersen during any time in their pregnancy

The main questions researchers want to learn about in this study are:

  • Loss of pregnancy overall
  • Loss of pregnancy before the baby was 20 weeks old
  • Loss of pregnancy after the baby becomes 20 weeks old
  • Live births
  • Loss of the baby after birth
  • Babies who have problems in their body that develop during pregnancy
  • Babies who are small for their age while in the participant's uterus
  • Pregnancy that happens outside of the uterus
  • How many participants die during pregnancy, while the baby is being born, and up to 12 weeks after delivering the baby
  • Babies who develop problems in their body after birth

Researchers will also compare this information to people without SMA who have not received nusinersen.

This study will be done as follows:

  • Information will start being collected when the participant decides to join the study.
  • Participants will be contacted at each trimester (about every 3 months) to learn about their health and pregnancy.
  • Participants' doctors will be contacted at each trimester, when the participants are about 6 or 7 months pregnant, and about 4 weeks after the delivery of the baby.
  • The babies' doctors will be contacted when the baby is 1, 2, 6, 12, 18, and 24 months old.
  • Each participant will be in the study until the end of their pregnancy and for up to 12 weeks after delivery. Each baby will be in the study for up to 2 years after birth.
  • The study overall will last at least 10 years from when the first participant joins the study.

Conditions

Muscular Atrophy, Spinal

Study ID

NCT05789758

Start date

Dec 15, 2023

Status verified date

Mar, 2026

Completion date

Oct 31, 2033

Anticipated

Primary completion date

Oct 31, 2032

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: Female

Age: 18 - 54

Healthy Volunteers: Not accepted

Key Inclusion Criteria:

  • Participant who is currently pregnant (or was pregnant during the relevant exposure window) and enrolled in the United States (US) network of the ISMAR registry, the United Kingdom (UK) Adult SMA REACH, or the Germany, Austria, or Switzerland network of the SMArtCARE registry
  • Genetic documentation of spinal muscular atrophy linked to chromosome 5q (5q SMA)
  • Documentation that the participant was exposed to nusinersen up to 14 months prior to the first day of their LMP before conception, 14.5 months before conception, and/or at any time during their pregnancy

Key Exclusion Criteria:

  • Treatment with risdiplam at any time from the first day of their LMP, 2 weeks prior to the date of conception (approximately 5 half-lives), and/or plans to receive treatment with risdiplam during pregnancy

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply

Study Design

Enrollment

20 participants

Anticipated

Interventions and Outcome Measures

Arms

Nusinersen Treated Participants

Pregnant participants with SMA who are exposed to nusinersen during the relevant window defined as 14 months prior to the first day of the participant's last menstrual period before conception, 14.5 months before conception and anytime during pregnancy and are enrolled in the registries, International Spinal Muscular Atrophy Registry (ISMAR), Adult SMA REACH and SMArtCARE will be followed prospectively up to 3 months post-delivery, the infants will be followed up to 2 years post-delivery and the available data is collected retrospectively.

Interventions

No Intervention

Administered as specified in the treatment arm.

Primary outcome measure

  • Number of Pregnancy Terminations [ Time Frame: Up to 10 years ]
  • Number of Spontaneous Abortions [ Time Frame: Up to 10 years ]
  • Number of Fetal Deaths [ Time Frame: Up to 10 years ]
  • Number of Live Births [ Time Frame: Up to 10 years ]
  • Number of Neonatal, Perinatal, and Infant Deaths [ Time Frame: Up to 10 years ]
  • Number of Major Congenital Malformations (MCMs) [ Time Frame: Up to 10 years ]
  • Number of Infants Small for Gestational Age Birth [ Time Frame: Up to 10 years ]
  • Number of Ectopic and Molar Pregnancies [ Time Frame: Up to 10 years ]
  • Number of Maternal Deaths [ Time Frame: Up to 10 years ]
  • Number of Infants With Abnormal Postnatal Growth and Development and Neurobehavioral Impairment [ Time Frame: Up to 10 years ]

Central Contacts and Locations

Central contacts

US Biogen Clinical Trial Center

866-633-4636clinicaltrials@biogen.com

Global Biogen Clinical Trial Center

clinicaltrials@biogen.com

Locations

Stanford Neuroscience Health Center

Recruiting

Palo Alto, California, United States, 94304

Contacts

Principal Investigator:

John W. Day

Boston Children's Hospital

Recruiting

Boston, Massachusetts, United States, 02115

Contacts

Principal Investigator:

Basil T. Darras

Columbia University Irving Medical Center

Recruiting

New York, New York, United States, 10032

Contacts

Principal Investigator:

Michio Hirano

More Information

Sponsor

Biogen

Last update posted

Mar 9, 2026

Last verified

Mar, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Biogen on 2026-03-09.